Interleukin-13 Antagonist [EPC]

6706 reported adverse events

Drugs of this class: LEBRIKIZUMAB-LBKZ TRALOKINUMAB-LDRM

These side effects are most commonly reported by patients taking drugs of the Interleukin-13 Antagonist [EPC] class:

# Side effect Count
0 DERMATITIS ATOPIC 900
1 DRUG INEFFECTIVE 856
2 PRURITUS 735
3 RASH 496
4 ECZEMA 465
5 INJECTION SITE PAIN 432
6 DRY SKIN 287
7 INJECTION SITE ERYTHEMA 239
8 ERYTHEMA 225
9 PRODUCT USE IN UNAPPROVED INDICATION 223
See all common reactions for Interleukin-13 Antagonist [EPC]

Drugs of the Interleukin-13 Antagonist [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 PRODUCT ADMINISTRATION ISSUE 8 0.0383
1 MOOD DISORDER DUE TO A GENERAL MEDICAL CONDITION 6 0.0247
2 EYE SYMPTOM 8 0.0224
3 DERMATITIS ATOPIC 900 0.0171
4 EYELID SKIN DRYNESS 18 0.0148
5 ACTIVITIES OF DAILY LIVING DECREASED 9 0.0141
6 ECZEMA HERPETICUM 6 0.0130
7 EYELID EXFOLIATION 8 0.0101
8 ECZEMA EYELIDS 5 0.0089
9 ECZEMA 465 0.0089
See all enriched reactions for Interleukin-13 Antagonist [EPC]